NeuroTherapia Raises $123M in First Close of Series B Funding
NeuroTherapia's Funding Announcement
NeuroTherapia Inc., a clinical-stage biotech company, has announced the first close of its Series B financing round, raising $123 million.
Phase 2a Clinical Trial
NeuroTherapia will utilize the funds to advance its Phase 2a clinical trial for NTRX-07, a novel therapeutic for neurodegenerative diseases.
Cleveland Clinic Innovations Partnership
NeuroTherapia, a portfolio company of Cleveland Clinic Innovations, is focused on developing innovative treatments for neurodegenerative diseases.
Komentar